|
AstraZeneca enters agreement with Recordati for Seloken in Europe
|
22 May 2017 |
|
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
|
12 May 2017 |
|
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
|
02 May 2017 |
|
First collaborative definition of patient centricity
|
05 April 2017 |
|
Tagrisso (osimertinib) receives US FDA full approval
|
31 March 2017 |
|
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
|
28 March 2017 |
|
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
|
17 March 2017 |
|
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
|
07 March 2017 |
|
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
|
28 February 2017 |
|
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
|
20 February 2017 |